Clinical trial
A Phase I Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Relapsed or Refractory Indolent B-Cell Hematologic Malignancies.
NCT03588598 is registered in ClinicalTrials.gov with Nanjing Sanhome Pharmaceutical, Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Relapsed or Refractory Indolent B-Cell Hematologic Malignancies.
- Lead sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- September 7, 2018
- Completion date
- December 31, 2019
- Enrollment
- 40 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
b-cell non-hodgkin lymphomas(nhl), chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll)